AMGEN INC. DL-,0001/ US0311621009 /
2024-04-24 9:08:21 PM | Chg. -0.150 | Volume | Bid7:36:54 AM | Ask7:36:54 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
255.600EUR | -0.06% | 40 Turnover: 10,028 |
255.300Bid Size: 1,000 | 256.100Ask Size: 1,000 | 136.75 bill.EUR | - | - |
GlobeNewswire
04-24
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeti...
GlobeNewswire
04-23
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...
GlobeNewswire
04-15
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
GlobeNewswire
04-15
Shah Capital nominates two highly qualified independent director candidates for Novavax
GlobeNewswire
04-08
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual ...
GlobeNewswire
04-08
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Dire...
GlobeNewswire
04-05
CORRECTION -- NeuroVigil, World’s Most Valuable Neurotech Company, Launches in US
GlobeNewswire
04-04
Over 52 Million Myeloma Warriors Reached, Creating Ripples Across the Globe for #MyelomaACTIONMonth
GlobeNewswire
04-03
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engag...
GlobeNewswire
03-25
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate ...
GlobeNewswire
03-25
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Director...
GlobeNewswire
03-20
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update